Articles by Tyler Menichiello

  1. A Call To Re-Evaluate Islet-Cell Regulations 8/15/2024

    Autologous islet cell transplantation (AIT) is regulated differently than allogeneic islet cell transplantation, which requires a BLA. Imagine Pharma's Dr. Rita Bottino makes the case for changing these regulations to better serve patients with Type 1 diabetes.

  2. Integrating Analytics And Automation In Cell Therapy Manufacturing 7/31/2024

    Experts from last month’s Cell & Gene Live event discuss practical ways to utilize emerging technologies.

  3. Manufacturing CAR-T In Vivo 7/25/2024

    Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.

  4. Rocket Pharma's Modality-Agnostic Approach To Rare Disease 7/24/2024

    Rocket Pharmaceuticals’ president, COO, and head of R&D, Dr. Kinnari Patel, discusses the company’s modality-agnostic approach to treating rare diseases.

  5. Building A Universal AAV For Cancer 6/28/2024

    "Universal" isn't the first word most people think of when they think about AAVs. But what if there were such a thing? Siren Biotechnology's CEO, Dr. Nicole Paulk, shares the story behind developing the company's universal AAV immuno-gene therapy.

  6. The Rising Tide Of Ophthalmologic Gene Therapies 6/27/2024

    There’s an explosion of clinical activity in the gene therapy space for inherited retinal diseases (IRDs). Atsena Therapeutics' CMO, Dr. Kenji Fujita, explains what makes IRDs such appealing gene therapy targets and shares the company’s strategic approach to clinical development.

  7. Using Stem Cells As An Immunologic 'Trojan Horse' 5/23/2024

    The immune system makes therapeutic delivery challenging, even for immunotherapies. Learn how Calidi Biotherapeutics is using stem cells to sneak oncolytic viruses past the immune system to the sites of solid tumors.

  8. Growing Livers In Lymph Nodes, A Lesson On Working With Nature 5/22/2024

    Dr. Michael Hufford, CEO of LyGenesis, believes in leveraging natural biology to develop cell therapies. Learn how the company’s doing so to grow ectopic livers inside patients with end-stage liver disease.

  9. Treating Alzheimer's With NK Cell Therapy 5/8/2024

    I met with NKGen Biotech's CEO, Dr. Paul Song, MD, to learn how a serendipitous discovery shifted the company's clinical focus from cancer to Alzheimer's disease.

  10. Pioneering The First Cell Therapy For Solid Tumors 4/26/2024

    I spoke to Iovance Biotherapeutics to learn about the company's preparation leading up to the approval of Amtagvi, the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors.